{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:51:27Z","timestamp":1790913087082,"version":"4.1.0"},"reference-count":173,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>\n                    As the most lethal gynecologic oncological indication, carcinoma of the ovary has been ranked as the 5\n                    <jats:sup>th<\/jats:sup>\n                    cause of cancer-related mortality in women, with a high percentage of the patients being diagnosed at late stages of the disease and a five-year survival of ~ 30%. Ovarian cancer patients conventionally undergo surgery for tumor removal followed by platinum- or taxane-based chemotherapy; however, a high percentage of patients experience tumor relapse. Cancer immunotherapy has been regarded as a silver lining in the treatment of patients with various immunological or oncological indications; however, mirvetuximab soravtansine (a folate receptor \u03b1-specific mAb) and bevacizumab (a VEGF-A-specific mAb) are the only immunotherapeutics approved for the treatment of ovarian cancer patients. Chimeric antigen receptor T-cell (CAR-T) therapy has achieved tremendous clinical success in the treatment of patients with certain B-cell lymphomas and leukemias, as well as multiple myeloma. In the context of solid tumors, CAR-T therapies face serious obstacles that limit their therapeutic benefit. Such hindrances include the immunosuppressive nature of solid tumors, impaired tumor infiltration, lack of qualified tumor-associated antigens, and compromised stimulation and persistence of CAR-Ts following administration. Over the past years, researchers have made arduous attempts to apply CAR-T therapy to ovarian cancer. In this review, we outline the principles of CAR-T therapy and then highlight its limitations in the context of solid tumors. Ultimately, we focus on preclinical and clinical findings achieved in CAR-T-mediated targeting of different ovarian cancer-associated target antigens.\n                  <\/jats:p>","DOI":"10.3389\/fimmu.2023.1302307","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T04:11:28Z","timestamp":1701922288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":31,"title":["CAR-T cell immunotherapy for ovarian cancer: hushing the silent killer"],"prefix":"10.3389","volume":"14","author":[{"given":"Fatemeh","family":"Nasiri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Farrokhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pouya","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maral","family":"Mahboubi Kancha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Setareh","family":"Dashti Shokoohi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pooria","family":"Safarzadeh Kozani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(13)62146-7","article-title":"Ovarian cancer","volume":"384","author":"Jayson","year":"2014","journal-title":"Lancet"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2018.08.005","article-title":"Surgical prevention strategies in ovarian cancer","volume":"151","author":"Mallen","year":"2018","journal-title":"Gynecol Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1097\/01.NPR.0000450742.00077.a2","article-title":"Ovarian cancer: Ensuring early diagnosis","volume":"40","author":"Slatnik","year":"2015","journal-title":"Nurse Practitioner"},{"key":"B4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1017\/S0025727300000521","article-title":"From the \u201cSilent killer\u201d to the \u201cWhispering disease\u201d: ovarian cancer and the uses of metaphor","volume":"53","author":"Jasen","year":"2009","journal-title":"Med History"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/igc.0000000000001118","article-title":"Ovarian cancer prevention, screening, and early detection: report from the 11th biennial ovarian cancer research symposium","volume":"27","author":"Chien","year":"2017","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"B6","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics, 2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: Cancer J Clin"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2019.02.001","article-title":"Ovarian cancer: an integrated review","volume":"35","author":"Stewart","year":"2019","journal-title":"Semin Oncol Nurs"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdj978","article-title":"Challenges for chemotherapy in ovarian cancer","author":"Ozols","year":"2006","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"key":"B9","article-title":"Surgical debulking of ovarian cancer: what difference does it make","volume":"3","author":"Schorge","year":"2010","journal-title":"Rev Obstet Gynecol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s12032-019-1287-8","article-title":"The role of radiotherapy in epithelial ovarian cancer: a literature overview","volume":"36","author":"Iorio","year":"2019","journal-title":"Med Oncol (Northwood London England)"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.02105","article-title":"Tumor-infiltrating lymphocytes and their prognostic value in cutaneous melanoma","volume":"11","author":"Maibach","year":"2020","journal-title":"Front Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s40425-016-0165-6","article-title":"Clinical significance of tumor-infiltrating lymphocytes in breast cancer","volume":"4","author":"Stanton","year":"2016","journal-title":"J Immunother Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139","article-title":"Type, density, and location of immune cells within human colorectal tumors predict clinical outcome","volume":"313","author":"Galon","year":"2006","journal-title":"Sci (New York NY)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.12551","article-title":"Decreased density of CD3+ tumor-infiltrating lymphocytes during gastric cancer progression","volume":"29","author":"Arigami","year":"2014","journal-title":"J Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177","article-title":"Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer","volume":"348","author":"Zhang","year":"2003","journal-title":"N Engl J Med"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.7182\/prtr.1.6.3.8145l3u185493182","article-title":"Ten years of Orthoclone OKT3 (muromonab-CD3): a review","volume":"6","author":"Smith","year":"1996","journal-title":"J Transpl Coord"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-2337","article-title":"FDA approval: blinatumomab for patients with B-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"Jen","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-17-3179","article-title":"FDA approval: gemtuzumab ozogamicin for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia","volume":"24","author":"Jen","year":"2018","journal-title":"Clin Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-18-2035","article-title":"FDA approval summary: tisagenlecleucel for treatment of patients with relapsed or refractory B-cell precursor acute lymphoblastic leukemia","volume":"25","author":"O'Leary","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11684-021-0901-2","article-title":"CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a sweet success","volume":"16","author":"Safarzadeh Kozani","year":"2022","journal-title":"Front Med"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1093\/abt\/tbab027","article-title":"US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives","volume":"4","author":"Wang","year":"2021","journal-title":"Antibody Ther"},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1084\/jem.178.1.1","article-title":"Analysis of T cell antigen receptor (TCR) expression by human peripheral blood CD4-8- alpha\/beta T cells demonstrates preferential use of several V beta genes and an invariant TCR alpha chain","volume":"178","author":"Porcelli","year":"1993","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1172\/jci157726","article-title":"Phase I study of adjuvant immunotherapy with autologous tumor-infiltrating lymphocytes in locally advanced cervical cancer","volume":"132","author":"Huang","year":"2022","journal-title":"J Clin Invest"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.109055","article-title":"CRISPR\/Cas9-medaited knockout of endogenous T-cell receptor in Jurkat cells and generation of NY-ESO-1-specific T cells: An in vitro study","volume":"110","author":"Safarzadeh Kozani","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002752","article-title":"Phase I dose escalation safety and feasibility study of autologous WT1-sensitized T cells for the treatment of patients with recurrent ovarian cancer","volume":"9","author":"Chrisann","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s40364-023-00509-1","article-title":"Site-specific transgene integration in chimeric antigen receptor (CAR) T cell therapies","volume":"11","author":"Dabiri","year":"2023","journal-title":"Biomark Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"4016","DOI":"10.1038\/s41467-019-11869-4","article-title":"CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors","volume":"10","author":"Jin","year":"2019","journal-title":"Nat Commun"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209650","article-title":"T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor model","volume":"113","author":"Di Stasi","year":"2009","journal-title":"Blood"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1063838","article-title":"T-cells engineered with a novel VHH-based chimeric antigen receptor against CD19 exhibit comparable tumoricidal efficacy to their FMC63-based counterparts","volume":"14","author":"Nasiri","year":"2023","journal-title":"Front Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1080\/07388551.2021.1988509","article-title":"Addressing the obstacles of CAR T cell migration in solid tumors: wishing a heavy traffic","volume":"42","author":"Safarzadeh Kozani","year":"2022","journal-title":"Crit Rev Biotechnol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.765097","article-title":"Optimizing the clinical impact of CAR-T cell therapy in B-cell acute lymphoblastic leukemia: looking back while moving forward","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front Immunol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.2.811","article-title":"Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma","volume":"181","author":"Piali","year":"1995","journal-title":"J Exp Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V88.2.667.bloodjournal882667","article-title":"Tumor angiogenesis is accompanied by a decreased inflammatory response of tumor-associated endothelium","volume":"88","author":"Griffioen","year":"1996","journal-title":"Blood"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1215\/s1152851705000232","article-title":"The role of pericytes in blood-vessel formation and maintenance","volume":"7","author":"Bergers","year":"2005","journal-title":"Neuro Oncol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1172\/jci45817","article-title":"Matrix architecture defines the preferential localization and migration of T cells into the stroma of human lung tumors","volume":"122","author":"Salmon","year":"2012","journal-title":"J Clin Invest"},{"key":"B36","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1172\/jci93554","article-title":"The fibrotic tumor stroma","volume":"128","author":"Yamauchi","year":"2018","journal-title":"J Clin Invest"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1720948115","article-title":"Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti-PD-1 treatment","volume":"115","author":"Peranzoni","year":"2018","journal-title":"Proc Natl Acad Sci USA"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.1701041","article-title":"Metabolic barriers to T cell function in tumors","volume":"200","author":"Sugiura","year":"2018","journal-title":"J Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.ccell.2019.05.004","article-title":"Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors","volume":"35","author":"Dangaj","year":"2019","journal-title":"Cancer Cell"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nature14404","article-title":"Melanoma-intrinsic \u03b2-catenin signalling prevents anti-tumour immunity","volume":"523","author":"Spranger","year":"2015","journal-title":"Nature"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02293","article-title":"WNT\/\u03b2-catenin signaling pathway regulating T cell-inflammation in the tumor microenvironment","volume":"10","author":"Li","year":"2019","journal-title":"Front Immunol"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795164","article-title":"Recent advances in solid tumor CAR-T cell therapy: driving tumor cells from hero to zero","volume":"13","author":"Safarzadeh Kozani","year":"2022","journal-title":"Front Immunol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1018786","article-title":"CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil","volume":"13","author":"Nasiri","year":"2022","journal-title":"Front Immunol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.11.028","article-title":"CAR T cells targeting MISIIR for the treatment of ovarian cancer and other gynecologic Malignancies","volume":"28","author":"Rodriguez-Garcia","year":"2020","journal-title":"Mol Ther"},{"key":"B46","doi-asserted-by":"publisher","first-page":"S116","DOI":"10.1016\/S0090-8258(22)01433-0","article-title":"Olfactory receptor OR5V1 is an effective target for CAR T cells in ovarian cancer (207)","volume":"166","author":"Martin","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.24152","article-title":"Targeting of embryonic annexin A2 expressed on ovarian and breast cancer by the novel monoclonal antibody 2448","volume":"9","author":"Cua","year":"2018","journal-title":"Oncotarget"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/308976","article-title":"Annexin A2: its molecular regulation and cellular expression in cancer development","volume":"2014","author":"Wang","year":"2014","journal-title":"Dis Markers"},{"key":"B49","doi-asserted-by":"publisher","first-page":"381","DOI":"10.3390\/ijms21020381","article-title":"Preclinical activity of embryonic annexin A2-specific chimeric antigen receptor T cells against ovarian cancer","volume":"21","author":"Leong","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B50","doi-asserted-by":"publisher","first-page":"5942","DOI":"10.3390\/ijms20235942","article-title":"CSPG4 as target for CAR-T-cell therapy of various tumor entities-merits and challenges","volume":"20","author":"Harrer","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2990.2002.00412.x","article-title":"The glial precursor proteoglycan, NG2, is expressed on tumour neovasculature by vascular pericytes in human Malignant brain tumours","volume":"28","author":"CheKenya","year":"2002","journal-title":"Neuropathol Appl Neurobiol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01911","article-title":"Chondroitin sulfate proteoglycan 4 and its potential as an antibody immunotherapy target across different tumor types","volume":"8","author":"Ilieva","year":"2017","journal-title":"Front Immunol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-148X.2011.00929.x","article-title":"CSPG4, a potential therapeutic target, facilitates Malignant progression of melanoma","volume":"24","author":"Price","year":"2011","journal-title":"Pigment Cell Melanoma Res"},{"key":"B54","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.3390\/cancers14205033","article-title":"Decitabine-mediated upregulation of CSPG4 in ovarian carcinoma cells enables targeting by CSPG4-specific CAR-T cells","volume":"14","author":"Harrer","year":"2022","journal-title":"Cancers"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1209319","article-title":"Regulation of high molecular weight-melanoma associated antigen (HMW-MAA) gene expression by promoter DNA methylation in human melanoma cells","volume":"25","author":"Luo","year":"2006","journal-title":"Oncogene"},{"key":"B56","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.ccell.2022.04.001","article-title":"Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia","volume":"40","author":"Leick","year":"2022","journal-title":"Cancer Cell"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101318","article-title":"Chondroitin sulfate proteoglycan 4, a targetable oncoantigen that promotes ovarian cancer growth, invasion, cisplatin resistance and spheroid formation","volume":"16","author":"Yang","year":"2022","journal-title":"Transl Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.3390\/ijms20112764","article-title":"CSPG4-specific CAR T cells for high-risk childhood B cell precursor leukemia","volume":"20","author":"Harrer","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.Cd-nb2018-032","article-title":"CSPG4 shows promise for glioblastoma CAR T therapy","volume":"8","year":"2018","journal-title":"Cancer Discovery"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-20-1089","article-title":"In like a lamb; out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL","volume":"20","author":"Safarzadeh Kozani","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-5183","article-title":"Abstract 5183: LGR5 CAR-T cells: A novel potential treatment against high grade serous ovarian cancer","volume":"82","author":"Wang","year":"2022","journal-title":"Cancer Res"},{"key":"B62","doi-asserted-by":"publisher","first-page":"5184","DOI":"10.1158\/1538-7445.Am2022-5184","article-title":"Abstract 5184: Real-time cytotoxicity assays as a pre-clinical screening tool for LGR5-targeting CAR-T cells for treatment of solid tumors","volume":"82","author":"Thompson","year":"2022","journal-title":"Cancer Res"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-5574","article-title":"Abstract 5574: In vivo characterization of a novel CAR-T cell therapy directed towards LGR5 for the treatment of colorectal cancer","volume":"82","author":"McPeake","year":"2022","journal-title":"Cancer Res"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-5575","article-title":"Abstract 5575: Pre-clinical validation of a LGR5-targeting CAR-T against colorectal cancer","volume":"82","author":"Bandara","year":"2022","journal-title":"Cancer Res"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00099","article-title":"CAR T cells redirected to CD44v6 control tumor growth in lung and ovary adenocarcinoma bearing mice","volume":"11","author":"Porcellini","year":"2020","journal-title":"Front Immunol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41419-018-1265-7","article-title":"CD44v6 engages in colorectal cancer progression","volume":"10","author":"Ma","year":"2019","journal-title":"Cell Death Dis"},{"key":"B67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.yexmp.2008.12.003","article-title":"Role of CD44s and CD44v6 on human breast cancer cell adhesion, migration, and invasion","volume":"86","author":"Afify","year":"2009","journal-title":"Exp Mol Pathol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0003360","article-title":"CD44s and CD44v6 expression in head and neck epithelia","volume":"3","author":"Mack","year":"2008","journal-title":"PloS One"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105259","article-title":"CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head\/neck squamous cell carcinoma cells","volume":"116","author":"Haist","year":"2021","journal-title":"Oral Oncol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1043","article-title":"CD44v6 chimeric antigen receptor T cell specificity towards AML with FLT3 or DNMT3A mutations","volume":"12","author":"Tang","year":"2022","journal-title":"Clin Transl Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-493361","article-title":"CD44v6-targeted T cells mediate potent antitumor effects against acute myeloid leukemia and multiple myeloma","volume":"122","author":"Casucci","year":"2013","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.216","article-title":"Characterization and functional analysis of CD44v6.CAR T cells endowed with a new low-affinity nerve growth factor receptor-based spacer","volume":"32","author":"Stornaiuolo","year":"2021","journal-title":"Hum Gene Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-12-2199","article-title":"PD-L1 on tumor cells is induced in ascites and promotes peritoneal dissemination of ovarian cancer through CTL dysfunction","volume":"19","author":"Abiko","year":"2013","journal-title":"Clin Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41392-022-01198-2","article-title":"A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis","volume":"7","author":"Ma","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.34","article-title":"Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo","volume":"1","author":"Guo","year":"2020","journal-title":"MedComm"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000203","article-title":"Preclinical assessment of CAR T-cell therapy targeting the tumor antigen 5T4 in ovarian cancer","volume":"41","author":"Owens","year":"2018","journal-title":"J Immunother"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-019-02419-4","article-title":"Preclinical development of T-cell receptor-engineered T-cell therapy targeting the 5T4 tumor antigen on renal cell carcinoma","volume":"68","author":"Xu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02268","article-title":"Effective targeting of TAG72+ Peritoneal ovarian tumors via regional delivery of CAR-engineered T cells","volume":"9","author":"Murad","year":"2018","journal-title":"Front Immunol"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0222-9","article-title":"Safety, tumor trafficking and immunogenicity of chimeric antigen receptor (CAR)-T cells specific for TAG-72 in colorectal cancer","volume":"5","author":"Hege","year":"2017","journal-title":"J Immunother Cancer"},{"key":"B80","article-title":"Humanized chimeric antigen receptor (CAR) T cells","volume":"3","author":"Safarzadeh Kozani","year":"2021","journal-title":"J Cancer Immunol (Wilmington)"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.01.002","article-title":"Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer","volume":"20","author":"Shu","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2007.070152","article-title":"Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule","volume":"171","author":"Trzpis","year":"2007","journal-title":"Am J Pathol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.20-0455","article-title":"Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model","volume":"83","author":"Fu","year":"2021","journal-title":"J Vet Med Sci"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.Am2022-2813","article-title":"Abstract 2813: Identification of a novel tumor marker combination THY1-EPCAM for adaptor CAR T cell therapy in ovarian cancer","volume":"82","author":"Herbel","year":"2022","journal-title":"Cancer Res"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1806009","article-title":"Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models","volume":"9","author":"Qin","year":"2020","journal-title":"OncoImmunology"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14592","article-title":"Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis","volume":"8","author":"Ang","year":"2017","journal-title":"Oncotarget"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1186\/s12865-014-0064-x","article-title":"Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM","volume":"16","author":"Deng","year":"2015","journal-title":"BMC Immunol"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.229","article-title":"Preclinical evaluation of chimeric antigen receptor-modified T cells specific to epithelial cell adhesion molecule for treating colorectal cancer","volume":"30","author":"Zhang","year":"2019","journal-title":"Hum Gene Ther"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1186\/2051-1426-3-S2-P32","article-title":"Targeting FR\u03b2+ tumor associated macrophages with car T cells in ovarian cancer","volume":"3","author":"Lynn","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-11-612721","article-title":"Targeting of folate receptor \u03b2 on acute myeloid leukemia blasts with chimeric antigen receptor\u2013expressing T cells","volume":"125","author":"Lynn","year":"2015","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.35","article-title":"High-affinity FR\u03b2-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity","volume":"30","author":"Lynn","year":"2016","journal-title":"Leukemia"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.05.9311","article-title":"T-cell immunity to the folate receptor alpha is prevalent in women with breast or ovarian cancer","volume":"24","author":"Knutson","year":"2006","journal-title":"J Clin Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.11.020","article-title":"Folate receptor alpha as a tumor target in epithelial ovarian cancer","volume":"108","author":"Kalli","year":"2008","journal-title":"Gynecol Oncol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.489","article-title":"Folate receptor alpha expression in lung cancer: diagnostic and prognostic significance","volume":"3","author":"O'Shannessy","year":"2012","journal-title":"Oncotarget"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1067\/mtc.2001.111176","article-title":"The alpha folate receptor is highly activated in Malignant pleural mesothelioma","volume":"121","author":"Bueno","year":"2001","journal-title":"J Thorac Cardiovasc Surg"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.21712","article-title":"The role of folate receptor alpha in cancer development, progression and treatment: cause, consequence or innocent bystander","volume":"119","author":"Kelemen","year":"2006","journal-title":"Int J Cancer"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin Cancer Res"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1089\/104303400750038480","article-title":"Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer","volume":"11","author":"Parker","year":"2000","journal-title":"Hum Gene Ther"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.4161\/cbt.26106","article-title":"The antitumor activity of the human FOLR1-specific monoclonal antibody, farletuzumab, in an ovarian cancer mouse model is mediated by antibody-dependent cellular cytotoxicity","volume":"14","author":"Lin","year":"2013","journal-title":"Cancer Biol Ther"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4071","article-title":"A fully human chimeric antigen receptor with potent activity against cancer cells but reduced risk for off-tumor toxicity","volume":"6","author":"Song","year":"2015","journal-title":"Oncotarget"},{"key":"B101","doi-asserted-by":"publisher","first-page":"82354","DOI":"10.18632\/oncotarget.10510","article-title":"Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo","volume":"7","author":"Xu","year":"2016","journal-title":"Oncotarget"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2021.101079","article-title":"Novel antigens of CAR T cell therapy: New roads; old destination","volume":"14","author":"Safarzadeh Kozani","year":"2021","journal-title":"Transl Oncol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2020.12.005","article-title":"Co-expression patterns of chimeric antigen receptor (CAR)-T cell target antigens in primary and recurrent ovarian cancer","volume":"160","author":"Banville","year":"2021","journal-title":"Gynecol Oncol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol Cancer"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.9191","article-title":"C-terminus of MUC16 activates Wnt signaling pathway through its interaction with \u03b2-catenin to promote tumorigenesis and metastasis","volume":"7","author":"Liu","year":"2016","journal-title":"Oncotarget"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-10-0192","article-title":"Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen","volume":"16","author":"Chekmasova","year":"2010","journal-title":"Clin Cancer Res"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2012.30.15_suppl.2586","article-title":"Effect of modulation of the hostile tumor microenvironment through adoptive transfer of IL-12 expressing MUC-16 targeted T cells on ovarian tumors in vivo","volume":"30","author":"Chekmasova","year":"2012","journal-title":"J Clin Oncol"},{"key":"B108","doi-asserted-by":"publisher","first-page":"e994446","DOI":"10.4161\/2162402x.2014.994446","article-title":"IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo","volume":"4","author":"Koneru","year":"2015","journal-title":"Oncoimmunology"},{"key":"B109","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s12967-015-0460-x","article-title":"A phase I clinical trial of adoptive T cell therapy using IL-12 secreting MUC-16(ecto) directed chimeric antigen receptors for recurrent ovarian cancer","volume":"13","author":"Koneru","year":"2015","journal-title":"J Transl Med"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.5_suppl.12","article-title":"Interleukin-12 armored chimeric antigen receptor (CAR) T cells for heterogeneous antigen-expressing ovarian cancer","volume":"36","author":"Yeku","year":"2018","journal-title":"J Clin Oncol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1158\/1557-3265.Ovca19-ia21","article-title":"Abstract IA21: MUC16-directed immunotherapy for ovarian cancer","volume":"26","author":"Yeku","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B112","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1186\/s12885-020-07180-x","article-title":"Therapeutic effect of dual CAR-T targeting PDL1 and MUC16 antigens on ovarian cancer cells in mice","volume":"20","author":"Li","year":"2020","journal-title":"BMC Cancer"},{"key":"B113","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1016\/j.ygyno.2020.06.089","article-title":"A phase I clinical trial of autologous chimeric antigen receptor (CAR) T cells genetically engineered to secrete IL-12 and to target the MUC16ecto antigen in patients (pts) with MUC16ecto+ recurrent high-grade serous ovarian cancer (HGSOC)","volume":"159","author":"O'Cearbhaill","year":"2020","journal-title":"Gynecol Oncol"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1016\/s0065-230x(06)95007-6","article-title":"NK cell receptors as tools in cancer immunotherapy","volume":"95","author":"Sentman","year":"2006","journal-title":"Adv Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1038\/85321","article-title":"Costimulation of CD8alphabeta T cells by NKG2D via engagement by MIC induced on virus-infected cells","volume":"2","author":"Groh","year":"2001","journal-title":"Nat Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.8.4480","article-title":"NKG2D is a costimulatory receptor for human naive CD8+ T cells","volume":"174","author":"Maasho","year":"2005","journal-title":"J Immunol"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.175.5.2825","article-title":"Costimulation through NKG2D enhances murine CD8+ CTL function: similarities and differences between NKG2D and CD28 costimulation","volume":"175","author":"Markiewicz","year":"2005","journal-title":"J Immunol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.96.12.6879","article-title":"Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB","volume":"96","author":"Groh","year":"1999","journal-title":"Proc Natl Acad Sci USA"},{"key":"B119","article-title":"Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity","volume":"62","author":"Pende","year":"2002","journal-title":"Cancer Res"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1034\/j.1399-0039.2003.00070.x","article-title":"NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer","volume":"61","author":"Cerwenka","year":"2003","journal-title":"Tissue Antigens"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1038\/nri1199","article-title":"Roles of the NKG2D immunoreceptor and its ligands","volume":"3","author":"Raulet","year":"2003","journal-title":"Nat Rev Immunol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-06-4047","article-title":"Chimeric NKG2D receptor\u2013bearing T cells as immunotherapy for ovarian cancer","volume":"67","author":"Barber","year":"2007","journal-title":"Cancer Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.1.72","article-title":"Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer","volume":"180","author":"Barber","year":"2008","journal-title":"J Immunol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1089\/hum.2012.143","article-title":"Chimeric NKG2D CAR-expressing T cell-mediated attack of human ovarian cancer is enhanced by histone deacetylase inhibition","volume":"24","author":"Song","year":"2013","journal-title":"Hum Gene Ther"},{"key":"B125","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell Malignancies: Is success a low-hanging fruit","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1038\/icb.2013.17","article-title":"NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors","volume":"91","author":"Spear","year":"2013","journal-title":"Immunol Cell Biol"},{"key":"B127","doi-asserted-by":"publisher","first-page":"e23564","DOI":"10.4161\/onci.23564","article-title":"Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors","volume":"2","author":"Spear","year":"2013","journal-title":"OncoImmunology"},{"key":"B128","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","article-title":"T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication","volume":"29","author":"Ng","year":"2021","journal-title":"Mol Ther"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03247-9","article-title":"Dual CAR-T cells to treat cancers co-expressing NKG2D and PD1 ligands in xenograft models of peritoneal metastasis","volume":"72","author":"Jiang","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.31083\/j.ceog4910227","article-title":"Romidepsin Enhances the Killing Ability of NKG2D-CAR-T Cells through Enhanced Expression of NKG2DL against Ovarian Cancer Cells","volume":"49","author":"Wang","year":"2022","journal-title":"CEOG"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910500308","article-title":"Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium","volume":"50","author":"Chang","year":"1992","journal-title":"Int J Cancer"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.1.136","article-title":"Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers","volume":"93","author":"Chang","year":"1996","journal-title":"Proc Natl Acad Sci U.S.A."},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.Ccr-11-2614","article-title":"Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients","volume":"18","author":"Servais","year":"2012","journal-title":"Clin Cancer Res"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.20.8.2902-2906.2000","article-title":"Mesothelin is not required for normal mouse development or reproduction","volume":"20","author":"Bera","year":"2000","journal-title":"Mol Cell Biol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-14-0337","article-title":"Discovery of mesothelin and exploiting it as a target for immunotherapy","volume":"74","author":"Pastan","year":"2014","journal-title":"Cancer Res"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.256","article-title":"Redirected antitumor activity of primary human lymphocytes transduced with a fully human anti-mesothelin chimeric receptor","volume":"20","author":"Lanitis","year":"2012","journal-title":"Mol Ther"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.34.15_suppl.5511","article-title":"Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer","volume":"34","author":"Tanyi","year":"2016","journal-title":"J Clin Oncol"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000160","article-title":"Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells","volume":"40","author":"Tanyi","year":"2017","journal-title":"J Immunother"},{"key":"B139","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1016\/j.jamcollsurg.2017.07.645","article-title":"Mesothelin chimeric antigen receptor (CAR)-mediated therapy for ovarian cancer","volume":"225","author":"Gruzdyn","year":"2017","journal-title":"J Am Coll Surgeons"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2018.08.583","article-title":"Inhibition of IL-10 augments mesothelin chimeric antigen receptor T cell activity in epithelial ovarian cancer","volume":"227","author":"Batchu","year":"2018","journal-title":"J Am Coll Surgeons"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.080","article-title":"Development of anti-human mesothelin-targeted chimeric antigen receptor messenger RNA-transfected peripheral blood lymphocytes for ovarian cancer therapy","volume":"29","author":"Hung","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2019.07.015","article-title":"Phase I study of lentiviral-transduced chimeric antigen receptor-modified T cells recognizing mesothelin in advanced solid cancers","volume":"27","author":"Haas","year":"2019","journal-title":"Mol Ther"},{"key":"B143","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s40364-022-00371-7","article-title":"Nanobody-based CAR-T cells for cancer immunotherapy","volume":"10","author":"Safarzadeh Kozani","year":"2022","journal-title":"biomark Res"},{"key":"B144","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1038\/s41419-019-1711-1","article-title":"Modified CAR T cells targeting membrane-proximal epitope of mesothelin enhances the antitumor function against large solid tumor","volume":"10","author":"Zhang","year":"2019","journal-title":"Cell Death Dis"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1016\/j.humimm.2020.12.002","article-title":"PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells","volume":"82","author":"Liu","year":"2021","journal-title":"Hum Immunol"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-20-2701","article-title":"Mesothelin-specific CAR T cells target ovarian cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.63181","article-title":"Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer","volume":"17","author":"Liang","year":"2021","journal-title":"Int J Biol Sci"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1016\/j.yexcr.2021.112886","article-title":"Disruption of adenosine 2A receptor improves the anti-tumor function of anti-mesothelin CAR T cells both in vitro and in vivo","volume":"409","author":"Liu","year":"2021","journal-title":"Exp Cell Res"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1016\/j.omto.2021.02.013","article-title":"The antitumor capacity of mesothelin-CAR-T cells in targeting solid tumors in mice","volume":"20","author":"Zhang","year":"2021","journal-title":"Mol Ther Oncolytics"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03290-6","article-title":"Dominant-negative transforming growth factor-\u03b2 receptor-armoured mesothelin-targeted chimeric antigen receptor T cells slow tumour growth in a mouse model of ovarian cancer","volume":"72","author":"Li","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J Hematol Oncol"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.4086","article-title":"IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor","volume":"36","author":"Adachi","year":"2018","journal-title":"Nat Biotechnol"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-022-03238-w","article-title":"Anti-mesothelin CAR-T immunotherapy in patients with ovarian cancer","volume":"72","author":"Chen","year":"2023","journal-title":"Cancer Immunol Immunother"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1016\/S0090-8258(22)01537-2","article-title":"Phase I study of autologous T cells bearing fully-humanized chimeric antigen receptors targeting mesothelin in mesothelin- expressing cancers (314)","volume":"166","author":"Tanyi","year":"2022","journal-title":"Gynecol Oncol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-023-01834-3","article-title":"Mirvetuximab soravtansine: first approval","volume":"83","author":"Heo","year":"2023","journal-title":"Drugs"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0782-5","article-title":"Durvalumab: first global approval","volume":"77","author":"Syed","year":"2017","journal-title":"Drugs"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-017-0749-6","article-title":"Avelumab: first global approval","volume":"77","author":"Kim","year":"2017","journal-title":"Drugs"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-016-0618-8","article-title":"Atezolizumab: first global approval","volume":"76","author":"Markham","year":"2016","journal-title":"Drugs"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-15-0159","article-title":"Affinity-tuned ErbB2 or EGFR chimeric antigen receptor T cells exhibit an increased therapeutic index against tumors in mice","volume":"75","author":"Liu","year":"2015","journal-title":"Cancer Res"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0951-5","article-title":"Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma","volume":"35","author":"Lin","year":"2021","journal-title":"Leukemia"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.627549","article-title":"Strategies for dodging the obstacles in CAR T cell therapy","volume":"11","author":"Safarzadeh Kozani","year":"2021","journal-title":"Front Oncol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/cancers11050674","article-title":"CAR T-cells targeting the integrin \u03b1v\u03b26 and co-expressing the chemokine receptor CXCR2 demonstrate enhanced homing and efficacy against several solid Malignancies","volume":"11","author":"Whilding","year":"2019","journal-title":"Cancers"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0192-1","article-title":"CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity","volume":"37","author":"Choi","year":"2019","journal-title":"Nat Biotechnol"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.4","article-title":"Enhancing antitumor efficacy of chimeric antigen receptor T cells through constitutive CD40L expression","volume":"23","author":"Curran","year":"2015","journal-title":"Mol Ther"},{"key":"B165","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.ccell.2019.02.006","article-title":"CD40 ligand-modified chimeric antigen receptor T cells enhance antitumor function by eliciting an endogenous antitumor response","volume":"35","author":"Kuhn","year":"2019","journal-title":"Cancer Cell"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T cells in relapsed\/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat Med"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1038\/nature21405","article-title":"Targeting a CAR to the TRAC locus with CRISPR\/Cas9 enhances tumour rejection","volume":"543","author":"Eyquem","year":"2017","journal-title":"Nature"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2018.02.025","article-title":"Long terminal repeat CRISPR-CAR-coupled \u201cUniversal\u201d T cells mediate potent anti-leukemic effects","volume":"26","author":"Georgiadis","year":"2018","journal-title":"Mol Ther"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013","article-title":"Molecular remission of infant B-ALL after infusion of universal TALEN gene-edited CAR T cells","volume":"9","author":"Qasim","year":"2017","journal-title":"Sci Trans Med"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-01-405365","article-title":"A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR","volume":"119","author":"Torikai","year":"2012","journal-title":"Blood"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2015.104","article-title":"A multidrug-resistant engineered CAR T cell for allogeneic combination immunotherapy","volume":"23","author":"Valton","year":"2015","journal-title":"Mol Ther"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-03-478255","article-title":"Toward eliminating HLA class I expression to generate universal cells from allogeneic donors","volume":"122","author":"Torikai","year":"2013","journal-title":"Blood"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15218","article-title":"A versatile system for rapid multiplex genome-edited CAR T cell generation","volume":"8","author":"Ren","year":"2017","journal-title":"Oncotarget"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1302307\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T04:11:33Z","timestamp":1701922293000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1302307\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":173,"alternative-id":["10.3389\/fimmu.2023.1302307"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1302307","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"article-number":"1302307"}}